This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jaffer, F. A. Articles by Weissleder, R. Search for Related Content PubMed PubMed Citation Articles by Jaffer, F. A. Articles by Weissleder, R. Related Collections Cardiovascular imaging agents/Techniques Imaging Coagulation CT and MRI Nuclear cardiology and PET

(Circulation. 2007;116:1052-1061.)
© 2007 American Heart Association, Inc.

Contemporary Reviews in Cardiovascular Medicine

Molecular Imaging of Cardiovascular Disease

Farouc A. Jaffer, MD, PhD; Peter Libby, MD; Ralph Weissleder, MD, PhD

From the Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Charlestown (F.A.J., R.W.); Donald W. Reynolds Cardiovascular Clinical Research Center, Harvard Medical School, Boston, Mass (F.A.J., P.L., R.W.); Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (P.L.); and Cardiovascular Research Center and Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (F.A.J.).

Correspondence to Farouc Jaffer, MGH-CMIR, 149 13th St, Room 5406, Charlestown, MA 02129. E-mail fjaffer{at}mgh.harvard.edu

Key Words: atherosclerosis • magnetic resonance imaging • thrombosis • myocardial infarction • diagnostic imaging

	Introduction

Top Introduction Imaging Agents Imaging Hardware Platforms Addressing Unmet Needs Molecular Imaging in... Outlook References

 
Molecular imaging aims at sensing specific molecular targets, fundamental biological processes, and certain cell types in living subjects. An integrative discipline rooted in the biological, chemical, and imaging sciences, molecular imaging has broad applications in biology and drug discovery^1–5 and increasingly within cardiovascular disease.^6–12 Before discussing key factors spurring the growth of this field, we first briefly review 2 essential components of this technology: imaging agents and imaging hardware.

	Imaging Agents

Top Introduction Imaging Agents Imaging Hardware Platforms Addressing Unmet Needs Molecular Imaging in... Outlook References

 
Molecular imaging requires highly sensitive and specific imaging agents. Such agents incorporate 2 key factors: (1) a signal detection compound and the corresponding imaging hardware platform and (2) an affinity ligand that recognizes the intended molecular or cellular target. Favorable targets include those with established biological and clinical importance in a disease of interest, as well as targets with inherent signal amplification potential such as internalizing receptors or enzymes. Inaccessible and low-abundance targets (DNA, RNA, sparsely expressed proteins) present greater challenges, particularly in a noninvasive, clinical setting.

Signal detection compounds include radioisotopes for positron emission tomography (PET) and single-photon-emission computed tomography (SPECT) imaging, paramagnetic (gadolinium)/superparamagnetic (iron oxide) agents for magnetic resonance imaging (MRI), fluorochromes for near-infrared fluorescence imaging, and microbubbles for ultrasound imaging. Certain agents can exhibit unique physical changes favorable for signal amplification when spaced close together (eg, quenching of fluorochromes^13–18 or augmented relaxivity of magnetic substrates^19–21). These tags can form the basis of imaging agents with inherent chemical amplification capabilities. Amplification strategies generally enable higher target-to-background ratios, a key strategy for developing sufficiently sensitive agents for clinical use.

Affinity ligands confer molecular or cellular specificity for the target of interest. The application of novel ligand screening methods, emerging new chemistries for conjugation and signal amplification, and nanotechnology have fostered substantial growth in ligand development. From a clinical perspective, qualities of an ideal ligand include (1) favorable kinetics to allow sensitive and fast detection, a particularly important consideration in the evaluation of acute thrombotic syndromes; (2) high sensitivity for its molecular target by using 1 or more signal amplification strategies; (3) a high degree of specificity for its molecular target; and (4) the ability to be readily conjugated to a range of signal detection compounds and still remain efficient as a targeting agent.

Initial cardiovascular molecular imaging studies primarily used radioisotope-derivatized monoclonal antibodies.²² Although specific, their larger size did not permit fast on/off rates and produced high target-to-background ratios in vivo. More efficient ligands now use smaller molecules such as antibody fragments, peptides, or carbohydrates derived from biochemical or cellular screens. Newer efforts use screening methods such as phage display,^23–25 nanoparticle libraries,²⁶ or diversity-oriented synthesis.²⁷ Additional considerations for reporter agents include whether their signal moiety or affinity ligand supports multivalency, defined as the conjugation of multiple ligands to the signal moiety^24,25 or the conjugation of multiple signal compounds to an affinity ligand.²³ Multivalent approaches can facilitate delivery of high payloads of signal compounds at the target, dramatically increasing the sensitivity of the agent. Growth in imaging reporters has particularly capitalized on developments in nanotechnology because nano-scale scaffolds and materials are well-suited to support multivalency for affinity ligands and colinked therapeutic molecules.^12,26,28 From the comparatively large number of new agents anticipated in the next 5 years, several candidates should emerge as promising clinical imaging agents (the Table)^29–49 on the basis of their high sensitivity, molecular specificity, lack of toxicity, favorable pharmacokinetics, cost, and relative ease of synthesis.

View this table: [in this window] [in a new window]   Clinically Promising Molecular Imaging Agents in Cardiovascular Disease (Partial List*)

	Imaging Hardware Platforms

Top Introduction Imaging Agents Imaging Hardware Platforms Addressing Unmet Needs Molecular Imaging in... Outlook References

 
The choice of imaging platform for a clinical molecular imaging study depends on a variety of factors, including the inherent sensitivity, spatial and temporal resolution, depth penetration, range of detection systems (noninvasive, invasive), radiation exposure, throughput, cost, and the availability of high-quality imaging agents for the desired molecular target. For example, assessing a primary tumor in cancer imaging often presents a much larger, static target than a coronary atheroma. Cardiovascular imaging studies thus require high-resolution strategies for both vascular (eg, atherosclerosis detection) and myocardial (eg, differentiating endocardium from epicardium) applications that must also overcome cardiac and respiratory motion and blood flow. In addition, favorable platforms allow concomitant assessment of cardiovascular anatomy and function. A number of promising modalities are available for clinical cardiovascular molecular imaging, either as standalone or fusion technologies, such as MRI⁹ and integrated nuclear/computed tomography (CT) systems (PET/CT, SPECT/CT).⁵⁰ Emerging modalities include optical imaging (in particular, intravascular near-infrared fluorophore [NIRF] reflectance,⁵¹ and fluorescence-mediated tomographic imaging⁵²), as well as integrated PET/MRI⁵³ and fluorescence-mediated tomography integrated with CT, MRI, or ultrasound.

	Addressing Unmet Needs

Top Introduction Imaging Agents Imaging Hardware Platforms Addressing Unmet Needs Molecular Imaging in... Outlook References

 
Why might molecular imaging prove clinically useful? Could such modalities provide useful information beyond that offered by anatomy- or physiology-based imaging? The answer is likely yes, because most diseases have an underlying biological basis that is not visualized by traditional imaging methods. Molecular imaging should prove a natural adjunct to personalized medicine by helping to tailor drug selection to an individual’s proteome and genome.^54,55 Imaging of important molecular targets could transform clinical management in the following situations.

Diagnosis and Risk Stratification
Several important questions remain unanswered in the current practice of clinical cardiology, among them the following. Which patients harbor high-risk atherosclerotic plaques that will ultimately cause myocardial infarction or stroke? Are there patients more likely to benefit from fibrinolysis in life-threatening thrombotic syndromes? Which post–myocardial infarction patients will develop pathological ventricular remodeling and rapid progression to heart failure? Direct visualization of the underlying biology in the diseased tissue may identify patients at high risk for cardiovascular complications, allowing the clinician to tailor management on the basis of risk. Specific examples of this capability in atherosclerosis, thrombosis, and myocardial infarction are discussed in the next section.

Selection and Efficacy Assessment of Molecule-Based Therapeutics
Many pharmaceuticals target specific molecules, cells, or biological processes. At present, the selection of such treatments depends on population-based studies or randomized clinical trials. Although quite powerful, such approaches do not routinely assess the biological variability of the disease process in individual patients. For example, do patients with nonischemic cadiomyopathy benefit from the potential antiinflammatory effects of statin therapy?⁵⁶ Perhaps myocardial imaging of statin-associated reductions in inflammation (as in atherosclerosis²⁵) could identify patients most likely to benefit. This new approach to targeting therapeutic agents will likely expand as new imaging agents and molecule-based therapeutics enter the clinic.

Conversion of Invasive Diagnostic Tests to Noninvasive Studies
Increased diagnostic sensitivity afforded by molecular imaging studies could offer noninvasive alternatives to invasive tests. As an example, endomyocardial biopsy is the reference standard to diagnose cardiac allograft rejection, but in addition to being invasive, it samples only a limited region of the ventricle. Sensitive, noninvasive methods to image cell death via annexin V SPECT imaging⁵⁷ or yet-to-be-developed agents or leukocyte infiltration via nanoparticle-enhanced MRI^58,59 could provide a safer, more comprehensive option to assess transplant rejection and antirejection therapies. As another example, noninvasive visualization of left atrial thrombi via fibrin-targeted MRI⁶⁰ might prove an attractive option to transesophageal echocardiography before urgent electric cardioversion for atrial fibrillation or before percutaneous mitral valvuloplasty.

Evaluation of Novel Pharmaceuticals in Clinical Trials
The decision to proceed from phase I/II to costly phase III clinical trials often is made without the knowledge of whether a new drug has achieved its intended molecular effect. To address this issue, there is substantial interest in evaluating biomarkers and surrogate end points as measures of drug efficacy in patients, with a major focus on serum biomarkers.^61,62 However, although frequently readily accessible, serum biomarkers often do not provide a readout of the action of a drug in the targeted diseased tissue. In contrast, imaging of inflammation (eg, via magnetic nanoparticle-enhanced MRI, [18F]-fluorodeoxyglucose [¹⁸FDG] PET imaging, or catheter-based protease NIRF imaging), for example, could provide a direct in vivo readout of novel antiinflammatory pharmaceuticals targeted to atherosclerosis.¹¹ Such measures also could complement methods that measure changes in atheroma volume such as multicontrast MRI or intravascular ultrasound. Consequently, new pharmaceuticals with positive phase I/II molecular imaging substudies might be ideal candidates to proceed to phase III studies in a cost-effective fashion.

	Molecular Imaging in Cardiovascular Medicine: Clinical Applications

Top Introduction Imaging Agents Imaging Hardware Platforms Addressing Unmet Needs Molecular Imaging in... Outlook References

 
Atherosclerosis
Unheralded rupture of high-risk atherosclerotic plaques causes many myocardial infarctions and sudden cardiac deaths.⁶³ Current imaging methodologies that typically image plaque anatomy do not identify such high-risk lesions. Identification of these lesions in relevant vascular beds (coronary and carotid arteries) could alter systemic therapies (ie, prescribing higher statin doses or adjunctive treatments despite "target" serum lipid levels) and possibly guide local therapies (eg, intracoronary stenting of high-risk lesions) in patients at very high risk. To meet this need, many molecular imaging studies of atherosclerosis target inflammation, a critical process underlying the progression and rupture of atherosclerotic lesions.⁶⁴ A number of imaging agents are emerging for atherosclerosis detection (reviewed elsewhere¹¹); here, we present leading candidates that could affect clinical practice considerably.

Imaging of Macrophages
Macrophages, key effector inflammatory cells in atherosclerosis,⁶⁴ abound in coronary plaques that have caused sudden cardiac death.⁶⁵ Imaging of macrophages is an appealing approach to detect inflammation in plaques prone to clinical complications.^6,7,11,66 Two clinical strategies have recently demonstrated success in this area: nanoparticle-enhanced MRI and ¹⁸FDG PET imaging.

Clinical dextran-coated magnetic nanoparticles (MNPs) consist of a 3-nm superparamagnetic iron oxide core that induces strong MRI contrast (signal reductions) on T2- and T2*-weighted images.⁶⁷ Clinical application of this compound has flourished in the detection of cancer metastases.⁶⁸ Recent investigations establish that MNPs can noninvasively image macrophages in carotid atheromata, with validation in carotid endarterectomy specimens (Figure 1).^29–33 MNP-enhanced MRI is now being explored as a surrogate end point in a randomized clinical trial of high-dose versus low-dose statin therapy, with the hypothesis that higher statin doses will better suppress macrophage accumulation in carotid atheromata.⁶⁹ Challenges of this approach stem from the intrinsic lower sensitivity of MRI compared with other imaging platforms, limiting the signal-to-noise ratio in high-resolution images required for coronary or carotid plaques. A potential gain in MNP imaging in the coronary arteries might be realized with intravascular MRI catheters.^70,71 In addition, new positive contrast sequences may augment the detection of MNPs in vivo.⁷² In the future, multimodality imaging nanoparticles for MRI and optical imaging⁷³ or novel MNPs that target vascular cell adhesion molecule-1^24,25 should expand the utility of MNPs in the clinic (Figure 2).

View larger version (123K): [in this window] [in a new window]   Figure 1. Noninvasive MRI of carotid plaque macrophages using dextran-coated iron oxide MNPs. A, Preinjection MRI (axial 3-mm section) of a patient 4.5 months after presentation with amaurosis fugax. B, Thirty-six hours after agent injection, focal signal loss evolves within the plaque (arrow). C, After endarterectomy, a collagen van Gieson stain depicts a thin fibrous cap (black arrowhead) overlying a large lipid core (white arrowhead; x1.5 magnification). D, Perls stain for iron and an immunohistochemical stain for macrophages confirm colocalization of MNPs (blue) with macrophages (brown; x40 magnification). Reproduced from Trivedi et al31 with permission from the American Academy of Neurology. Copyright 2004.

View larger version (67K): [in this window] [in a new window]   Figure 2. Experimental MRI of inflammation in atherosclerosis using multimodality magnetofluorescent nanoparticles (MFNP). A, Left, Twenty-four hours after MFNP injection, in vivo MRI of apolipoprotein E–/– mice demonstrates strong focal enhancement in aortic plaques that is (middle) also visualized on ex vivo near-infrared fluorescence reflectance imaging. Right, Fluorescence microscopy confirms MFNP deposition (red) in plaque macrophages rather than medial smooth muscle cells (green; immunofluorescently labeled with an -actin smooth muscle antibody). Images modified with permission from Jaffer et al.73 B, Left, In vivo imaging of inflammation in atherosclerosis using a vascular cell adhesion molecule-1 (VCAM-1) internalizing magnetic nanoparticle (VINP-28). In vivo MRI demonstrates focal signal loss in aortic plaques of apolipoprotein E–/– mice after VINP-28 injection (insets with and without pseudocoloring). Right, Compared with mice receiving a high-cholesterol diet (HCD), age-matched statin-treated mice demonstrate reductions in VCAM-1 expression that can be detected noninvasively with VINP-28–enhanced MRI. Adapted from Nahrendorf et al25 with permission from the American Heart Association. Copyright 2006.

¹⁸FDG is a glucose analog and positron emitter (half-life, 110 minutes) that concentrates in metabolically active cells after glucose transport and hexokinase-mediated phosphorylation.⁷⁴ Several recent studies demonstrate that this agent accumulates in carotid atheroma^34–37 and that its uptake correlates with macrophages as opposed to smooth muscle cells.³⁷ A recent gain has been in the integration of PET with high-resolution CT and/or MRI to allow reliable coregistration of molecular and anatomic information (Figure 3). With the development of a radiopharmaceutical network⁷⁵ spurred by the growth of cancer imaging studies,⁷⁶ PET imaging studies of vascular inflammation should expand considerably in the next several years, because centers will not require on-site cyclotrons. Similar to dextran-coated MNPs, several clinical trials are using ¹⁸FDG PET to quantify reductions in carotid plaque inflammation after statin pharmacotherapy.^38,69 Challenges of PET imaging include the need for ionizing radiation, a considerable limitation to screening low-risk subjects. Furthermore, the radiation exposure will increase if coronary or carotid CT angiography is performed concomitantly for anatomic coregistration.⁷⁷ In addition, ¹⁸FDG PET detection of macrophage-rich coronary plaques may suffer from substantial background uptake by metabolically active myocardium.⁶⁶ Potential methods to improve the utility of coronary plaque ¹⁸FDG PET imaging include suppression of myocardial ¹⁸FDG signal by high-fat/low-glucose diets or β-adrenergic blocker before imaging, ECG and respiratory gating, or possibly the use of intravascular radiation detectors that may preferentially detect radioisotopes physically near the catheter.⁷⁸ In addition, newer macrophage-specific targeted PET agents may overcome the limitation of background signal from metabolically active myocardium.

View larger version (85K): [in this window] [in a new window]   Figure 3. Integrated 18FDG PET/CT and subsequent coregistered MRI of carotid atherosclerotic plaques. A, Axial CT image demonstrates arterial wall calcification at the level of the carotid artery (red crosshairs). B, 18FDG PET image acquired 2 hours after agent injection reveals bilateral carotid 18FDG uptake (C) as confirmed on the PET/CT fusion image. D, High-resolution black-blood MRI of the right carotid artery shows 2 matching areas of calcification (blue arrows correspond to calcified lesions on CT). Courtesy of Drs James H. Rudd and Zahi A. Fayad, Mount Sinai School of Medicine.

Finally, 2 very recent developments in the imaging of macrophages in atherosclerosis also deserve comment. First, a new study demonstrates the ability to target plaque macrophages with gadolinium-loaded immunomicelles targeted to the macrophage scavenger receptor.⁷⁹ This agent may offer another MRI-based approach to image plaque macrophages. Second, a recent abstract demonstrates the ability to image macrophages with an iodine-loaded micelle (N1177) for CT.⁸⁰ This approach may be particularly useful because CT angiography is emerging as a powerful method to image coronary arteries. This agent could thus provide enhancement of macrophage-rich coronary atheroma during coronary CT angiography.

Imaging of Annexin V
Annexin V is a 36-kDa protein that binds to phosphatidylserine, a molecule exposed on the membranes of dying cells, and may identify a subset of plaques with high rates of apoptosis potentially at greater risk for future complications.^63,64 In a preliminary study of 4 patients, ^99mTc-radiolabeled annexin V (or annexin A5) preferentially localized in patients with recent rather than remote transient ischemic attacks and was associated with macrophage and annexin V staining on plaque sections.³⁹ However, annexin V in atheroma may target not only apoptotic cells in atheromata, with recent work showing colocalization of annexin V with nonapoptotic macrophages and with intraplaque hemorrhage.⁴⁰ As with PET, SPECT imaging requires ionizing radiation, a drawback particularly when applied to the screening of low-risk individuals. Additional gains in annexin V–based imaging may occur with new targeted radioisotopes for PET imaging⁸¹ or magnetic nanoparticles for MRI.⁸²

Imaging of Protease Activity
Augmented matrix metalloproteinase and cysteine protease expression occurs in the plaques of patients with atherosclerotic vascular disease.⁶⁴ Because of their matrix-degrading properties, proteases likely mediate plaque remodeling and rupture and thus delineate plaques prone to complications. Recent experiments have imaged augmented cysteine and matrix metalloproteinase activity in atherosclerotic mice using near-infrared fluorescence imaging reporters.^14,17,18 The strategy uses imaging agents that are quenched (silent) at baseline and then become strongly fluorescent after protease cleavage, producing a high signal-to-noise ratio in vivo (Figure 4). This strategy offers a new translational approach to image inflammation in atheroma.^8,11 Because NIRF imaging is suitable for clinical cardiovascular imaging,^83,84 we have recently constructed an NIRF catheter for intravascular imaging of protease activity.⁵¹ The catheter is a clinical-type guidewire that can be delivered percutaneously into coronary-sized vessels. In a recent experiment in atherosclerotic rabbits, a protease-activatable agent (Prosense750, VisEnMedical, Woburn, Mass) was administered intravenously, and the iliac vessels were imaged 24 hours later. Pullback of the intravascular NIRF catheter through blood, without the need for flushing, revealed strong focal NIRF signal in iliac plaques that was confirmed on ex vivo imaging (Figure 4).⁴² This approach may provide a high-resolution approach to image inflammation in coronary plaques and may identify high-risk lesions. Challenges of this approach include the limitations of photon attenuation and scattering with increasing depths and the semiquantitative and surface-weighted reflectance imaging, which may be addressable through the use of algorithms that correct for source-to-target variations in distance. In addition, the agent needs to undergo human testing in phase I clinical trials, currently planned for 2008.

View larger version (20K): [in this window] [in a new window]   Figure 4. Intravascular NIRF imaging of inflammation in experimental iliac atherosclerosis using a protease-activatable imaging agent (Prosense). A, Mechanism of agent activation. Cysteine proteases cleave the quenched substrate, resulting in strong NIRF signal. Image reproduced from Shah K, Weissleder R. NeuroRx. 2005;2:215–225 with permission from Elsevier. Copyright 2005 American Society for Experimental Neuotherapeutics. B, Twenty-fours after agent intravenous injection, a custom-built intravascular NIRF catheter51 was advanced percutaneously distal to a rabbit iliac atherosclerotic plaque. Catheter pullback through blood demonstrated strong focal NIRF signal in the plaque.42 Ex vivo fluorescence reflectance imaging corroborated these findings. Adapted from Jaffer et al42 with permission from the American Heart Association. Copyright 2006.

Imaging of Angiogenesis
Microvessels within evolving plaques may cause intraplaque hemorrhage and thus identify high-risk atherosclerotic lesions.^63,64 In particular, integrin _vβ₃ is a key mediator of angiogenesis and thus may represent an important diagnostic and therapeutic target for diseases characterized by neovascularization.⁸⁵ Recent experimental studies have used a gadolinium-coated perfluorocarbon nanomaterial (containing 90 000 gadolinium chelates) derivatized with an arginine-glycine-aspartic acid peptidomimetic to target _vβ₃. Noninvasive MRI of experimental atherosclerotic plaques showed the ability of the agent to image angiogenesis in aortic plaques with 20% to 30% signal increases over untargeted perfluorocarbon agents.⁴³ Very recent work has harnessed this nanoplatform to incorporate an antiangiogenic agent, fumagillin, to allow serial noninvasive MRI of antiangiogenic drug delivery and therapy.⁴⁴ As with other MRI imaging agents, the application to coronary lesions will likely require advances in MRI detection systems.^70,71

Thrombosis
Thrombosis is the hallmark of multiple cardiovascular diseases, including acute coronary syndromes, stroke, and pulmonary embolism. However, despite the availability of useful diagnostic methods for thrombosis, several important issues remain unresolved. For example, practitioners would welcome noninvasive options over invasive, standard tests such as invasive coronary angiography or transesophageal echocardiography. Can we a priori identify fibrinolytically responsive thrombi to maximize the benefit (reperfusion) -to-risk (intracerebral bleeding) ratio, perhaps by imaging biologically acute thrombi via thrombin activity,^15,86 activated factor XIII activity,⁸⁷ or fibrin burden?²³ Two recent advances in thrombosis reporter imaging agents for clinical use are highlighted next.

Imaging of Fibrin
Thrombin-mediated cleavage of fibrinogen yields fibrin monomers, which then polymerize and undergo cross-linking to form a stable clot. Both arterial and venous thrombi contain fibrin, making fibrin an appealing target for thrombosis imaging. Investigated as a scintigraphic imaging target almost 2 decades ago,⁸⁸ a recent advance has been the development of a small-molecule fibrin-targeted agent for MRI (EP-2104R, Epix Pharmaceuticals, Lexington, Mass).^{23,60,89–92} With a 10-fold improvement in spatial resolution over nuclear approaches, MRI is better suited to image smaller vessels such as the carotid and coronary arteries. Although cardiovascular MRI has well-appreciated advantages,⁹ the lower inherent sensitivity of MRI challenges the construction of molecular MRI agents. To overcome this limitation, the fibrin-targeted MRI agent capitalizes on 3 amplification strategies. First, the agent is based on a peptide, enabling faster binding kinetics compared with large-molecule (antibody) approaches, a key consideration in thrombosis detection. Second, the peptide was derived from phage-display screening technology and was selected to bind fibrin but not its precursor, fibrinogen; this property minimizes background signal from circulating fibrinogen, permitting faster detection of the enhanced thrombus. Third, the agent incorporates multivalency, with 4 gadolinium molecules conjugated to each peptide ligand, further increasing the thrombus target-to-background ratio. Extensive preclinical work has demonstrated considerable MRI enhancement of pulmonary embolism, atrial thrombi, and coronary stent thrombosis.^{23,60,89–91} In addition, a rigorous experimental study demonstrated that fibrin is a stable imaging target in various ages of thrombi (<6 hours to 1 month old),⁹² a feature that should further improve its sensitivity for clinical thrombosis detection.

The agent is now under investigation in phase I/II clinical trials in a range of thrombosis syndromes.⁴⁷ In a preliminary study of 52 patients imaged 2 to 24 hours after injection of the agent, there was substantial enhancement of atrial and ventricular thrombi, deep venous thrombosis, and carotid arterial thrombi (Figure 5). Several intriguing applications of high-resolution fibrin imaging include the detection of left atrial thrombi, offering a potential noninvasive option to transesophageal echocardiography, as discussed earlier. In addition, the agent improved the detection of recurrent deep venous thrombosis, a vexing problem for anatomic or flow-based diagnostic imaging methods. Further studies will determine whether the agent will permit rapid detection of thrombi (<1 hour after injection) in more urgent situations such as acute coronary syndromes or pulmonary embolism. Finally, a recent development in fibrin imaging is the development of fibrin-targeted nanoparticles for CT molecular imaging of thrombus.⁹³ Further in vivo investigation with this agent could augment the ability of CT to diagnose pulmonary embolism, stroke, or acute coronary syndromes.

View larger version (107K): [in this window] [in a new window]   Figure 5. Noninvasive MRI of thrombosis with a fibrin-targeted paramagnetic imaging agent (EP-2104R).47 After scout image acquisition and agent injection, postcontrast images (2- to 24-hour time points) revealed strong signal enhancement in a patient with likely right atrial thrombus, fibrinous pleuritis, and thrombus-bearing aortic plaque (A) and a patient with recurrent deep venous thrombosis (B; history of 2 prior deep venous thromboses), showing the full extent of the thrombus burden. Courtesy of Dr David Maintz, Universitätsklinikum Münster, Munster, Germany (A); Dr Manuel Martinez, Medica Sur, Mexico City, Mexico (B); and EPIX Medical.

Imaging of Platelets
Platelets are a major focus for modern antithrombotic therapies, and an important molecular target is the fibrin receptor integrin _IIbβ₃(glycoprotein IIb/IIIa), a-228 kDa heterodimeric protein that mediates platelet aggregation and promotes thrombus propagation.⁹⁴ A US Food and Drug Administration–approved agent for SPECT imaging of platelet glycoprotein IIb/IIIa is ^99mTc-apcitide (Berlex Laboratories, Wayne, NJ), an arginine-glycine-aspartic analog that competes with fibrinogen for binding to platelet glycoprotein IIb/IIIa. In a clinical trial of 78 patients, ^99mTc-apcitide SPECT imaging proved sensitive (92%) and specific (82% to 90%) for both a first deep venous thrombosis and a recurrent deep venous thrombosis.⁴⁵ As with EP-2104R, specific diagnosis of thrombosis may represent an advantage over traditional diagnostic methods, as was highlighted in a case report of a patient with recurrent pulmonary embolism.⁴⁶ Unexplored applications include the ability to image glycoprotein IIb/IIIa in coronary arterial thrombi to diagnose acute coronary syndromes and to guide and assess the effect of glycoprotein IIb/IIIa antagonists or other upstream platelet inhibitors. Because of the relatively low resolution of SPECT, such a study would likely require coronary CT angiography to visualize and anatomically coregister the coronary artery.

Myocardial Infarction
After myocardial infarction, a subset of patients may develop mechanical complications or ventricular dilatation and progression to heart failure. Identification of these at-risk patients has great potential to guide targeted clinical evaluation and pharmacological therapies. Accordingly, a number of preclinical imaging strategies have evolved for the detection of postinfarction matrix metalloproteinase activity, angiogenesis, activated factor XIIIa, apoptosis, macrophages, and stem cell delivery and thus offer new approaches to stratify subjects with myocardial infarction. Two recent developments in the clinical application of these approaches are discussed next.

Imaging of Angiogenesis
Angiogenesis, the growth of new blood vessels, modulates post–myocardial infarction healing and subsequent ventricular remodeling.^95,96 A preliminary SPECT study of 10 acute myocardial infarction patients used an integrin _vβ₃–targeted agent (^99mTc-NC100692, GE Healthcare, Oslo, Norway) to assess cardiac angiogenesis.⁴⁸ After percutaneous coronary revascularization, patients underwent perfusion imaging with ^99mTc-MIBI SPECT and echocardiography to assess the size of the infarct. Three weeks after myocardial infarction, ^99mTc-NC100692 SPECT imaging was performed to image infarct angiogenesis. Focal signal colocalized in the infarct zone, indicating angiogenesis in the healing infarct (Figure 6). Further analysis will reveal whether the extent of angiogenesis correlates with adverse ventricular remodeling and clinical outcome. This platform also may ultimately allow assessment of angiogenic therapies in post–myocardial infarction patients.

View larger version (76K): [in this window] [in a new window]   Figure 6. Noninvasive SPECT imaging of angiogenesis in a post–myocardial infarction patient after percutaneous coronary intervention. After injection of an integrin vβ3–targeted agent (99mTc-NC100692) 3 weeks after myocardial infarction, focal signal enhancement (arrowheads) is noted in the short-axis (A) and long-axis (B) views of the infarct zone, as confirmed by the corresponding 99mTc-MIBI perfusion images. Images courtesy of Drs Johan Verjans and Leonard Hofstra, University Hospital, Maastricht, the Netherlands.

Imaging of Stem Cells for Myocardial Regeneration
The prospect of cellular regeneration of failing hearts represents a new frontier for cardiovascular medicine. However, initial trials of stem cell transplantation after myocardial infarction have yielded mixed outcomes,^97,98 suggesting a need for imaging strategies to elucidate the in vivo distribution, engraftment, migration, and viability of transplanted stem cells. Recently, a human clinical trial of melanoma patients demonstrated the utility of both magnetic nanoparticles and ¹¹¹indium-oxine labeling to track dendritic cells in patients.⁴⁹ The results suggest that an analogous scheme could label cardiac-targeted stem cells before delivery to post–myocardial infarction patients. Given the high-resolution imaging capabilities of cardiac MRI, MNP labeling in particular could shed light on the fate of stem cells in the hearts of living subjects. Challenges of the approach include the potential loss of the MNPs or the ¹¹¹indium-oxine label with stem cell division and the possible transfer of the agents to nonstem cells such as macrophages.⁹⁹

	Outlook

Top Introduction Imaging Agents Imaging Hardware Platforms Addressing Unmet Needs Molecular Imaging in... Outlook References

 
Treatment of patients with cardiovascular disease increasingly incorporates molecular and cellular markers of disease into management algorithms. Molecular imaging will offer the ability to provide biological detail in patients and, although still in its infancy, shows promise for imaging of atherosclerosis, thrombosis, and myocardial infarction. Further growth in reporter imaging agents possessing nanotechnological amplification schemes and expansion of high-resolution imaging systems for nuclear/CT, MRI, and optical imaging should enable molecular imaging to become an integral component of personalized medicine.

	Acknowledgments

 
We would like to thank Ashvin Pande, MD, for assistance with reviewing the thrombosis imaging literature and Melissa Carlson for expert editorial assistance.

Sources of Funding

This work was supported by the Donald W. Reynolds Foundation (all authors), NIH UO1-HL080731 (all authors), NIH R01-HL078641 (Dr Weissleder), and American College of Cardiology Foundation Career Development Award (Dr Jaffer).

Disclosures

Dr Libby has received research grant support from the NIH and the Donald W. Reynolds Foundation. Dr Weissleder has received research grant support from the NIH and the Donald W. Reynolds Foundation and is a shareholder of VisEN Medical in Woburn, Mass. Dr Jaffer reports no conflicts.

	References

Top Introduction Imaging Agents Imaging Hardware Platforms Addressing Unmet Needs Molecular Imaging in... Outlook References

 
1. Weissleder R. Molecular imaging in cancer. Science. 2006; 312: 1168–1171.[Abstract/Free Full Text]

2. Herschman HR. Molecular imaging: looking at problems, seeing solutions. Science. 2003; 302: 605–608.[Abstract/Free Full Text]

3. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003; 2: 123–131.[CrossRef][Medline] [Order article via Infotrieve]

4. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspectives. J Clin Invest. 2003; 111: 1620–1629.[CrossRef][Medline] [Order article via Infotrieve]

5. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003; 17: 545–580.[Free Full Text]

6. Jaffer FA, Weissleder R. Seeing within: molecular imaging of the cardiovascular system. Circ Res. 2004; 94: 433–445.[Abstract/Free Full Text]

7. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov. 2004; 3: 913–925.[CrossRef][Medline] [Order article via Infotrieve]

8. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA. 2005; 293: 855–862.[Abstract/Free Full Text]

9. Fuster V, Kim RJ. Frontiers in cardiovascular magnetic resonance. Circulation. 2005; 112: 135–144.[Free Full Text]

10. Bonow RO. Molecular beacons illuminate subcellular events. Circulation. 2005; 111: 1730–1732.[Free Full Text]

11. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol. 2006; 47: 1328–1338.[Abstract/Free Full Text]

12. Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol. 2006; 26: 435–441.[Abstract/Free Full Text]

13. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999; 17: 375–378.[CrossRef][Medline] [Order article via Infotrieve]

14. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002; 105: 2766–2771.[Abstract/Free Full Text]

15. Jaffer FA, Tung CH, Gerszten RE, Weissleder R. In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arterioscler Thromb Vasc Biol. 2002; 22: 1929–1935.[Abstract/Free Full Text]

16. Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation. 2005; 111: 1800–1805.[Abstract/Free Full Text]

17. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006; 114: 55–62.[Abstract/Free Full Text]

18. Jaffer FA, Kim DE, Quinti L, Tung CH, Pande AN, AIkawa E, Kohler RH, Shi GP, Libby P, Weissleder R. Optical visualization of cathepsin K activity in atherosclerosis using a novel, protease-activatable fluorescence sensor. Circulation. 2007; 115: 2292–2298.[Abstract/Free Full Text]

19. Perez JM, Josephson L, O’Loughlin T, Hogemann D, Weissleder R. Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol. 2002; 20: 816–820.[Medline] [Order article via Infotrieve]

20. Chen JW, Pham W, Weissleder R, Bogdanov A Jr. Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magn Reson Med. 2004; 52: 1021–1028.[CrossRef][Medline] [Order article via Infotrieve]

21. Perez JM, Simeone FJ, Saeki Y, Josephson L, Weissleder R. Peroxidase substrate nanosensors for MR imaging. NanoLetters. 2004; 4: 119–122.

22. Khaw BA, Gold HK, Yasuda T, Leinbach RC, Kanke M, Fallon JT, Barlai-Kovach M, Strauss HW, Sheehan F, Haber E. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation. 1986; 74: 501–508.[Abstract/Free Full Text]

23. Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, Hamilton J, Quist W, Parsons EC Jr, Vaidya A, Kolodziej A, Barrett JA, Graham PB, Weisskoff RM, Manning WJ, Johnstone MT. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004; 109: 2023–2029.[Abstract/Free Full Text]

24. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005; 96: 327–336.[Abstract/Free Full Text]

25. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006; 114: 1504–1511.[Abstract/Free Full Text]

26. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005; 23: 1418–1423.[CrossRef][Medline] [Order article via Infotrieve]

27. Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science. 2000; 287: 1964–1969.[Abstract/Free Full Text]

28. Anderson DG, Levenberg S, Langer R. Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. Nat Biotechnol. 2004; 22: 863–866.[CrossRef][Medline] [Order article via Infotrieve]

29. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003; 107: 2453–2458.[Abstract/Free Full Text]

30. Trivedi RA, Mallawarachi C, U-King-Im JM, Graves MJ, Horsley J, Goddard MJ, Brown A, Wang L, Kirkpatrick PJ, Brown J, Gillard JH. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006; 26: 1601–1606.[Abstract/Free Full Text]

31. Trivedi RA, U-King-Im JM, Graves MJ, Kirkpatrick PJ, Gillard JH. Noninvasive imaging of carotid plaque inflammation. Neurology. 2004; 63: 187–188.[Free Full Text]

32. Trivedi RA, U-King-Im JM, Graves MJ, Cross JJ, Horsley J, Goddard MJ, Skepper JN, Quartey G, Warburton E, Joubert I, Wang L, Kirkpatrick PJ, Brown J, Gillard JH. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004; 35: 1631–1635.[Abstract/Free Full Text]

33. Tang T, Howarth SP, Miller SR, Trivedi R, Graves MJ, King-Im JU, Li ZY, Brown AP, Kirkpatrick PJ, Gaunt ME, Gillard JH. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke. 2006; 37: 2266–2270.[Abstract/Free Full Text]

34. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105: 2708–2711.[Abstract/Free Full Text]

35. Davies JR, Rudd JH, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, Gillard JH, Warburton EA, Weissberg PL. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005; 36: 2642–2647.[Abstract/Free Full Text]

36. Okane K, Ibaraki M, Toyoshima H, Sugawara S, Takahashi K, Miura S, Shimosegawa E, Satomi J, Kitamura K, Satoh T. 18F-FDG accumulation in atherosclerosis: use of CT and MR co-registration of thoracic and carotid arteries. Eur J Nucl Med Mol Imaging. 2006; 33: 589–594.[CrossRef][Medline] [Order article via Infotrieve]

37. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuragia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque information in patients. J Am Coll Cardiol. 2006; 48: 1818–1828.[Abstract/Free Full Text]

38. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006; 48: 1825–1831.[Abstract/Free Full Text]

39. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, Narula J. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med. 2004; 350: 1472–1473.[Free Full Text]

40. Wolters S, Appleby S, Tordoir J, Teule J, Daemen M, Reutelingsperger C, Narula J, Hofstra L. Annexin A5 targeting to unstable plaque is mainly related to activation of macrophages and intra plaque hemorrhage. Mol Imaging. 2006; 5: 223. Abstract/

41. Annovazzi A, Bonanno E, Arca M, D’Alessandria C, Marcoccia A, Spagnoli LG, Violi F, Scopinaro F, De Toma G, Signore A. ^99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2006; 33: 117–126.[CrossRef][Medline] [Order article via Infotrieve]

42. Jaffer FA, Nahrendorf M, Vinegoni C, John MC, Aikawa E, Uchihashi M, Finn AV, Ntziachristos V, Libby P, Gold HK, Weissleder R. In vivo imaging of protease activity in atherosclerosis using a near-infrared fluorescence intravascular catheter. Circulation. 2006; 114 (suppl II): II-410. Abstract.

43. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha (v) beta3-integrin-targeted nanoparticles. Circulation. 2003; 108: 2270–2274.[Abstract/Free Full Text]

44. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26: 2103–2109.[Abstract/Free Full Text]

45. Bates SM, Lister-James J, Julian JA, Taillefer R, Moyer BR, Ginsberg JS. Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis. Arch Intern Med. 2003; 163: 452–456.[Abstract/Free Full Text]

46. Davison JM, Bridwell R, Montilla JL, Jackson E, Moores LK. A novel diagnostic method for acute pulmonary embolism: technetium-99m apcitide scintigraphy. Ann Intern Med. 2004; 140: 936–939.[Free Full Text]

47. Vymzaal J, Spuentrup E, Cardenas G, Stefancik R, Hartmann M, Uprichard A. The use of a fibrin-binding magnetic resonance imaging agent P-2104R to visualize thrombi in the venous and arterial vasculature. Presented at: Radiological Society of North America Annual Meeting; November 26 to December 1, 2006; Chicago, Ill. Paper No. SSK06–07.

48. Verjans J, Wolters S, Laufer W, Boersma H, Lax M, Lovhaug D, Kemerink G, Teule J, Gordon P, Reutelingsperger C, Narula J, Hofstra L. Molecular imaging of avb3 expression to predict left ventricular remodeling in patients with myocardial infarction. Mol Imaging. 2006; 5: 224. Abstract.

49. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005; 23: 1407–1413.[CrossRef][Medline] [Order article via Infotrieve]

50. Di Carli MF, Dorbala S, Hachamovitch R. Integrated cardiac PET-CT for the diagnosis and management of CAD. J Nucl Cardiol. 2006; 13: 139–144.[CrossRef][Medline] [Order article via Infotrieve]

51. Zhu B, Jaffer FA, Ntziachristos V, Weissleder R. Development of a near infrared fluorescence catheter: operating characterisitics and feasibility for atherosclerotic plaque detection. J Phys D Appl Phys. 2005; 38: 2701–2707.[CrossRef]

52. Ntziachristos V, Tung CH, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med. 2002; 8: 757–760.[CrossRef][Medline] [Order article via Infotrieve]

53. Pichler BJ, Judenhofer MS, Catana C, Walton JH, Kneilling M, Nutt RE, Siegel SB, Claussen CD, Cherry SR. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med. 2006; 47: 639–647.[Abstract/Free Full Text]

54. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA. 2001; 286: 2211–2214.[Free Full Text]

55. Ginsburg GS, Donahue MP, Newby LK. Prospects for personalized cardiovascular medicine: the impact of genomics. J Am Coll Cardiol. 2005; 46: 1615–1627.[Abstract/Free Full Text]

56. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003; 108: 839–843.[Abstract/Free Full Text]

57. Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, Fitzpatrick JM, Raghunath PN, Tomaszewski JE, Kelly C, Steinmetz N, Green A, Tait JF, Leppo J, Blankenberg FG, Jain D, Strauss HW. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001; 7: 1347–1352.[CrossRef][Medline] [Order article via Infotrieve]

58. Kanno S, Wu YJ, Lee PC, Dodd SJ, Williams M, Griffith BP, Ho C. Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation. 2001; 104: 934–938.[Abstract/Free Full Text]

59. Wu YL, Ye Q, Foley LM, Hitchens TK, Sato K, Williams JB, Ho C. In situ labeling of immune cells with iron oxide particles: an approach to detect organ rejection by cellular MRI. Proc Natl Acad Sci U S A. 2006; 103: 1852–1857.[Abstract/Free Full Text]

60. Spuentrup E, Fausten B, Kinzel S, Wiethoff AJ, Botnar RM, Graham PB, Haller S, Katoh M, Parsons EC Jr, Manning WJ, Busch T, Gunther RW, Buecker A. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation. 2005; 112: 396–399.[Abstract/Free Full Text]

61. Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006; 113: 2936–2942.[Abstract/Free Full Text]

62. Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov. 2006; 5: 463–469.[CrossRef][Medline] [Order article via Infotrieve]

63. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003; 108: 1664–1672.[Abstract/Free Full Text]

64. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.[CrossRef][Medline] [Order article via Infotrieve]

65. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997; 336: 1276–1282.[Abstract/Free Full Text]

66. Davies JR, Rudd JH, Weissberg PL, Narula J. Radionuclide imaging for the detection of inflammation in vulnerable plaques. J Am Coll Cardiol. 2006; 47: C57–C68.[Abstract/Free Full Text]

67. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990; 175: 489–493.[Abstract/Free Full Text]

68. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003; 348: 2491–2499.[Abstract/Free Full Text]

69. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed March 15, 2007.

70. Larose E, Yeghiazarians Y, Libby P, Yucel EK, Aikawa M, Kacher DF, Aikawa E, Kinlay S, Schoen FJ, Selwyn AP, Ganz P. Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging. Circulation. 2005; 112: 2324–2331.[Abstract/Free Full Text]

71. Schneiderman J, Wilensky RL, Weiss A, Samouha E, Muchnik L, Chen-Zion M, Ilovitch M, Golan E, Blank A, Flugelman M, Rozenman Y, Virmani R. Diagnosis of thin-cap fibroatheromas by a self-contained intravascular magnetic resonance imaging probe in ex vivo human aortas and in situ coronary arteries. J Am Coll Cardiol. 2005; 45: 1961–1969.[Abstract/Free Full Text]

72. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med. 2005; 53: 999–1005.[CrossRef][Medline] [Order article via Infotrieve]

73. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol Imaging. 2006; 5: 85–92.[Medline] [Order article via Infotrieve]

74. Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol. 2001; 28: 1–4.[CrossRef][Medline] [Order article via Infotrieve]

75. PETNET Solutions. Available at: http://www.petnetsolutions.com/. Accessed August 10, 2007.

76. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354: 496–507.[Free Full Text]

77. Poon M. Technology insight: cardiac CT angiography. Nat Clin Pract Cardiovasc Med. 2006; 3: 265–275.[CrossRef][Medline] [Order article via Infotrieve]

78. Strauss HW, Mari C, Patt BE, Ghazarossian V. Intravascular radiation detectors for the detection of vulnerable atheroma. J Am Coll Cardiol. 2006; 47: C97–C100.[Abstract/Free Full Text]

79. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad ZA. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A. 2007; 104: 961–966.[Abstract/Free Full Text]

80. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007; 13: 636–641.[CrossRef][Medline] [Order article via Infotrieve]

81. Murakami Y, Takamatsu H, Taki J, Tatsumi M, Noda A, Ichise R, Tait JF, Nishimura S. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging. 2004; 31: 469–474.[CrossRef][Medline] [Order article via Infotrieve]

82. Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Reynolds F, Grazette L, Rosenzweig A, Weissleder R, Josephson L. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med. 2005; 54: 718–724.[CrossRef][Medline] [Order article via Infotrieve]

83. Taggart DP, Choudhary B, Anastasiadis K, Abu-Omar Y, Balacumaraswami L, Pigott DW. Preliminary experience with a novel intraoperative fluorescence imaging technique to evaluate the patency of bypass grafts in total arterial revascularization. Ann Thorac Surg. 2003; 75: 870–873.[Abstract/Free Full Text]

84. Desai ND, Miwa S, Kodama D, Cohen G, Christakis GT, Goldman BS, Baerlocher MO, Pelletier MP, Fremes SE. Improving the quality of coronary bypass surgery with intraoperative angiography: validation of a new technique. J Am Coll Cardiol. 2005; 46: 1521–1525.[Abstract/Free Full Text]

85. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264: 569–571.[Abstract/Free Full Text]

86. Badimon JJ, Fuster V. Can we image the "active" thrombus? Arterioscler Thromb Vasc Biol. 2002; 22: 1753–1754.[Free Full Text]

87. Jaffer FA, Tung CH, Wykrzykowska JJ, Ho NH, Houng AK, Reed GL, Weissleder R. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation. 2004; 110: 170–176.[Abstract/Free Full Text]

88. Jung M, Kletter K, Dudczak R, Koppensteiner R, Minar E, Kahls P, Stumpflen A, Pokieser P, Ehringer H. Deep vein thrombosis: scintigraphic diagnosis with In-111-labeled monoclonal antifibrin antibodies. Radiology. 1989; 173: 469–475.[Abstract/Free Full Text]

89. Botnar RM, Buecker A, Wiethoff AJ, Parsons EC Jr, Katoh M, Katsimaglis G, Weisskoff RM, Lauffer RB, Graham PB, Gunther RW, Manning WJ, Spuentrup E. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004; 110: 1463–1466.[Abstract/Free Full Text]

90. Spuentrup E, Buecker A, Katoh M, Wiethoff AJ, Parsons EC, Jr., Botnar RM, Weisskoff RM, Graham PB, Manning WJ, Gunther RW. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation. 2005; 111: 1377–1382.[Abstract/Free Full Text]

91. Spuentrup E, Katoh M, Wiethoff AJ, Parsons EC Jr, Botnar RM, Mahnken AH, Gunther RW, Buecker A. Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. Am J Respir Crit Care Med. 2005; 172: 494–500.[Abstract/Free Full Text]

92. Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, Toussaint JF, Fayad ZA. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005; 112: 1594–1600.[Abstract/Free Full Text]

93. Winter PM, Shukla HP, Caruthers SD, Scott MJ, Fuhrhop RW, Robertson JD, Gaffney PJ, Wickline SA, Lanza GM. Molecular imaging of human thrombus with computed tomography. Acad Radiol. 2005; 12 (suppl 1): S9–S13.[CrossRef][Medline] [Order article via Infotrieve]

94. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002; 8: 1227–1234.[CrossRef][Medline] [Order article via Infotrieve]

95. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004; 94: 1543–1553.[Abstract/Free Full Text]

96. Frangogiannis NG, Entman ML. Chemokines in myocardial ischemia. Trends Cardiovasc Med. 2005; 15: 163–169.[CrossRef][Medline] [Order article via Infotrieve]

97. Chien KR. Lost and found: cardiac stem cell therapy revisited. J Clin Invest. 2006; 116: 1838–1840.[CrossRef][Medline] [Order article via Infotrieve]

98. Rosenzweig A. Cardiac cell therapy: mixed results from mixed cells. N Engl J Med. 2006; 355: 1274–1277.[Free Full Text]

99. Frangioni JV, Hajjar RJ. In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation. 2004; 110: 3378–3383.[Abstract/Free Full Text]

This article has been cited by other articles:

				F. A. Jaffer Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging. J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1795 - 1796. [Full Text] [PDF]

				A. Maiseyeu, G. Mihai, T. Kampfrath, O. P. Simonetti, C. K. Sen, S. Roy, S. Rajagopalan, and S. Parthasarathy Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis J. Lipid Res., November 1, 2009; 50(11): 2157 - 2163. [Abstract] [Full Text] [PDF]

				M. Nahrendorf, E. Keliher, P. Panizzi, H. Zhang, S. Hembrador, J.-L. Figueiredo, E. Aikawa, K. Kelly, P. Libby, and R. Weissleder 18F-4V for PET-CT Imaging of VCAM-1 Expression in Atherosclerosis J. Am. Coll. Cardiol. Img., October 1, 2009; 2(10): 1213 - 1222. [Abstract] [Full Text] [PDF]

				P. K. Shah Imaging Inflammation in Atherosclerosis: Another Step Forward J. Am. Coll. Cardiol. Img., October 1, 2009; 2(10): 1223 - 1225. [Full Text] [PDF]

				D. E. Drachman Drug-Eluting Stents in Animals and Patients: Where Do We Stand Today? Circulation, July 14, 2009; 120(2): 101 - 103. [Full Text] [PDF]

				R. P. Choudhury and E. A. Fisher Molecular Imaging in Atherosclerosis, Thrombosis, and Vascular Inflammation Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 983 - 991. [Abstract] [Full Text] [PDF]

				F. A. Jaffer, P. Libby, and R. Weissleder Optical and Multimodality Molecular Imaging: Insights Into Atherosclerosis Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1017 - 1024. [Abstract] [Full Text] [PDF]

				A. M. Jansson, P. Aukrust, T. Ueland, C. Smith, T. Omland, M. Hartford, and K. Caidahl Soluble CXCL16 Predicts Long-Term Mortality in Acute Coronary Syndromes Circulation, June 30, 2009; 119(25): 3181 - 3188. [Abstract] [Full Text] [PDF]

				J. Wykrzykowska, S. Lehman, G. Williams, J. A. Parker, M. R. Palmer, S. Varkey, G. Kolodny, and R. Laham Imaging of Inflamed and Vulnerable Plaque in Coronary Arteries with 18F-FDG PET/CT in Patients with Suppression of Myocardial Uptake Using a Low-Carbohydrate, High-Fat Preparation J. Nucl. Med., April 1, 2009; 50(4): 563 - 568. [Abstract] [Full Text] [PDF]

				F. A. Jaffer, C. Vinegoni, M. C. John, E. Aikawa, H. K. Gold, A. V. Finn, V. Ntziachristos, P. Libby, and R. Weissleder Real-Time Catheter Molecular Sensing of Inflammation in Proteolytically Active Atherosclerosis Circulation, October 28, 2008; 118(18): 1802 - 1809. [Abstract] [Full Text] [PDF]

				M. J. Lipinski, K. C. Briley-Saebo, V. Mani, and Z. A. Fayad "Positive Contrast" Inversion-Recovery With Oxide Nanoparticles-Resonant Water Suppression Magnetic Resonance Imaging: A Change for the Better? J. Am. Coll. Cardiol., August 5, 2008; 52(6): 492 - 494. [Full Text] [PDF]

				C. von zur Muhlen, D. von Elverfeldt, J.A. Moeller, R.P. Choudhury, D. Paul, C.E. Hagemeyer, M. Olschewski, A. Becker, I. Neudorfer, N. Bassler, et al. Magnetic Resonance Imaging Contrast Agent Targeted Toward Activated Platelets Allows In Vivo Detection of Thrombosis and Monitoring of Thrombolysis Circulation, July 15, 2008; 118(3): 258 - 267. [Abstract] [Full Text] [PDF]

				M. J. Kern and J. Narula Looking into the vessel: the more you see, the more you want to see. J. Am. Coll. Cardiol. Img., July 1, 2008; 1(4): 556 - 559. [Full Text] [PDF]

				M. A. McAteer, J. E. Schneider, Z. A. Ali, N. Warrick, C. A. Bursill, C. von zur Muhlen, D. R. Greaves, S. Neubauer, K. M. Channon, and R. P. Choudhury Magnetic Resonance Imaging of Endothelial Adhesion Molecules in Mouse Atherosclerosis Using Dual-Targeted Microparticles of Iron Oxide Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 77 - 83. [Abstract] [Full Text] [PDF]

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jaffer, F. A. Articles by Weissleder, R. Search for Related Content PubMed PubMed Citation Articles by Jaffer, F. A. Articles by Weissleder, R. Related Collections Cardiovascular imaging agents/Techniques Imaging Coagulation CT and MRI Nuclear cardiology and PET